Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Lin, Ying Li ^a   Wang, Yan Ling ^b   Ma, Jian Guo ^c   Li, Wen Ping ^c  

^a JIANGSU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Bladder cancer; Methylation; PCDH8; Protocadherin 8

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; PROTOCADHERIN 8; UNCLASSIFIED DRUG; PCDH8 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AGED; BIOMARKERS, TUMOR; CADHERINS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 84906932949     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0068-7     Document Type: Article

References (33)

1. Cancer statistics, 2013. R1 Siegel, D Naishadham, A Jemal, CA Cancer J Clin 2013 63 1 11 30 10.3322/caac.21166 23335087
2. Bladder cancer. DS Kaufman, WU Shipley, AS Feldman, Lancet 2009 374 9685 239 249 10.1016/S0140-6736(09)60491-8 19520422
3. The global burden of urinary bladder cancer. DM Parkin, Scand J Urol Nephrol Suppl 2008 218 12 20 10.1080/03008880802285032 19054893
4. The present and future burden of urinary bladder cancer in the world. M Ploeg, KK Aben, LA Kiemeney, World J Urol 2009 27 3 289 293 10.1007/s00345-009-0383-3 19219610
5. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. S Van den Bosch, J Alfred Witjes, Eur Urol 2011 60 3 493 500 10.1016/j.eururo.2011.05.045 21664041
6. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. BW Van Rhijn, M Burger, Y Lotan, E Solsona, CG Stief, RJ Sylvester, JA Witjes, AR Zlotta, Eur Urol 2009 56 3 430 442 10.1016/j.eururo.2009.06.028 19576682
7. Non-invasive diagnosis bladder cancer: new molecular markers and future perspectives. M Musquera, L Mengual, MJ Ribal, Arch Esp Urol 2013 66 5 487 494 23793766
8. Tools to investigate biomarker expression in bladder cancer progression. C Galustian, BJU Int 2013 112 3 404 406 10.1111/j.1464-410X.2013.11792.x 23826845
9. DNA methylation-based biomarkers in bladder cancer. R Kandimalla, AA van Tilborg, EC Zwarthoff, Nat Rev Urol 2013 10 6 327 335 10.1038/nrurol.2013.89 23628807
10. Epigenetics of bladder cancer. WJ Kim, YJ Kim, Methods Mol Biol 2012 863 111 118 10.1007/978-1-61779-612-8-6 22359289
11. Non-clustered protocadherin. SY Kim, S Yasuda, H Tanaka, K Yamagata, H Kim, Cell Adh Migr 2011 5 2 97 105 10.4161/cam.5.2.14374 21173574
12. Clustered protocadherins. WV Chen, T Maniatis, Development 2013 140 16 3297 3302 10.1242/dev.090621 23900538
13. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer. YL Lin, JH Ma, XL Luo, TY Guan, ZG Li, J Int Med Res 2013 41 1 48 54 10.1177/0300060513475571 23569129
14. Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. D Zhang, W Zhao, X Liao, T Bi, H Li, X Che, Oncol Rep 2012 28 5 1785 1791 22941331
15. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. JS Yu, S Koujak, S Nagase, CM Li, T Su, X Wang, M Keniry, L Memeo, A Rojtman, M Mansukhani, H Hibshoosh, B Tycko, R Parsons, Oncogene 2008 27 34 4657 4665 10.1038/onc.2008.101 18408767
16. Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. D He, Q Zeng, G Ren, T Xiang, Y Qian, Q Hu, J Zhu, S Hong, G Hu, Eur J Cancer Prev 2012 21 6 569 575 10.1097/CEJ.0b013e328350b097 22273848
17. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. X Tang, X Yin, T Xiang, H Li, F Li, L Chen, G Ren, Cancer Biomark 2013 12 1 11 19
18. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. YL Lin, ZG Li, ZK He, TY Guan, JG Ma, J Int Med Res 2012 40 6 2117 2123 10.1177/030006051204000609 23321168
19. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. VL Costa, R Henrique, SA Danielsen, M Eknaes, P Patrício, A Morais, J Oliveira, RA Lothe, MR Teixeira, GE Lind, C Jerónimo, Epigenetics 2011 6 9 1120 1130 10.4161/epi.6.9.16376 21847011
20. PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer. Y Yang, J Liu, X Li, JC Li, Histol Histopathol 2012 27 2 217 224 22207556
21. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. I Imoto, H Izumi, S Yokoi, H Hosoda, T Shibata, F Hosoda, M Ohki, S Hirohashi, J Inazawa, Cancer Res 2006 66 9 4617 4626 10.1158/0008-5472.CAN-05-4437 16651412
22. The American Joint Committee on Cancer: updating the strategies in cancer staging. FL Greene, Bull Am Coll Surg 2002 87 7 13 15 17387902
23. Guidelines on bladder cancer. W Oosterlinck, B Lobel, G Jakse, PU Malmström, M Stöckle, C Sternberg, Eur Urol 2002 41 2 105 112 10.1016/S0302-2838(01)00026-4 12074395
24. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. M Babjuk, W Oosterlinck, R Sylvester, E Kaasinen, A Böhle, J Palou-Redorta, M Rouprêt, Eur Urol 2011 59 6 997 1008 10.1016/j.eururo.2011.03.017 21458150
25. Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence. H Li, J Wang, W Xiao, D Xia, B Lang, T Wang, X Guo, Z Hu, Z Ye, H Xu, J Urol 2014 191 2 493 501 10.1016/j.juro.2013.08.087 24018236
26. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. V Casadio, C Molinari, D Calistri, M Tebaldi, R Gunelli, L Serra, F Falcini, C Zingaretti, R Silvestrini, D Amadori, W Zoli, J Exp Clin Cancer Res 2013 32 1 94 10.1186/1756-9966-32-94 24252461
27. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. J Zhu, Y Wang, J Duan, H Bai, Z Wang, L Wei, J Zhao, M Zhuo, S Wang, L Yang, T An, M Wu, J Wang, J Exp Clin Cancer Res 2012 31 80 10.1186/1756-9966-31-80 23009178
28. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. N Wang, H Zhang, Q Yao, Y Wang, S Dai, X Yang, J Exp Clin Cancer Res 2012 31 6 10.1186/1756-9966-31-6 22248469
29. Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. C Rengucci, G De Maio, A Gardini, M Zucca, E Scarpi, C Zingaretti, G Foschi, M Tumedei, C Molinari, L Saragoni, M Puccetti, D Amadori, W Zoli, D Calistri, J Exp Clin Cancer Res 2014 33 1 65 10.1186/s13046-014-0065-x 25091577
30. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. JW Moon, SK Lee, JO Lee, N Kim, YW Lee, SJ Kim, HJ Kang, J Kim, HS Kim, SH Park, J Exp Clin Cancer Res 2014 33 4 10.1186/1756-9966-33-4 24393480
31. Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. X Cui, Z Zhao, D Liu, T Guo, S Li, J Hu, C Liu, L Yang, Y Cao, J Jiang, W Liang, W Liu, S Li, L Wang, L Wang, W Gu, C Wu, Y Chen, F Li, J Exp Clin Cancer Res 2014 33 20 10.1186/1756-9966-33-20 24528540
32. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. JG Herman, JR Graff, S Myöhänen, BD Nelkin, SB Baylin, Proc Natl Acad Sci U S A 1996 93 18 9821 9826 10.1073/pnas.93.18.9821 8790415
33. Establishment of diagnosis by bisulfite-treated methylation-specific PCR method and analysis of clinical characteristics of pseudohypoparathyroidism type 1b. K Kinoshita, M Minagawa, T Takatani, R Takatani, M Ohashi, Y Kohno, Endocr J 2011 58 10 879 887 10.1507/endocrj.K10E-364 21836370